New insights from MRI-guided laser interstitial thermal therapy for refractory epilepsy: a state-of-the-art overview - Takeaways - MDSpire

New insights from MRI-guided laser interstitial thermal therapy for refractory epilepsy: a state-of-the-art overview

  • By

  • Carlos Quispe-Vicuña

  • Fernando Terry

  • Miguel Cabanillas-Lazo

  • Alejandro Enríquez-Marulanda

  • Niels Pacheco-Barrios

  • Forough Yazdanian

  • J. Pierre Zila-Velasque

  • David R. Soriano-Moreno

  • Christian Moran-Mariños

  • Evan Luther

  • Lekhaj Daggubati

  • Martin Merenzon

  • Jaime Lopez-Calle

  • Jorge G. Burneo

  • Ricardo J. Komotar

  • Ziev B. Moses

  • John D. Rolston

  • Carlos Alva-Diaz

  • May 29, 2026

  • 0 min

Share

  • 1

    MRI-guided laser interstitial thermal therapy (MRgLITT) is a therapeutic option for drug-resistant epilepsy (DRE) without standardized clinical guidelines.

  • 2

    A systematic review of 16 systematic reviews revealed a seizure freedom rate for MRgLITT ranging from 18.87% to 75.86%.

  • 3

    Fourteen systematic reviews scored 'Critically low' on the AMSTAR-2 tool, indicating a lack of robust evidence for MRgLITT in DRE.

  • 4

    Common complications associated with MRgLITT include visual field deficits (2.17%-7.5%) and intracranial hemorrhage (0.96%-8.6%).

  • 5

    The overall certainty of evidence regarding MRgLITT for DRE was assessed as 'very low' due to the absence of randomized studies.

Original Source(s)

Related Content